Celcuity Inc. Common Stock
CELC
$82.27
-0.42%
Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors, with its lead candidate gedatolisib targeting the PI3K/AKT/mTOR pathway. The company is a niche player in precision oncology, differentiated by its comprehensive PAM pathway inhibition and a Phase 3 trial (VIKTORIA-1) in HR+/HER2- breast cancer that has completed enrollment. The current investor narrative centers on the upcoming FDA review and potential approval of gedatolisib, which has driven a massive stock rally, but recent price volatility reflects debates around clinical data, regulatory risk, and the path to commercialization.…
CELC
Celcuity Inc. Common Stock
$82.27
Related headlines
Investment Opinion: Should I buy CELC Today?
Rating: Speculative Buy. Thesis: Celcuity offers a high-risk, high-reward opportunity centered on the FDA approval of gedatolisib, with analyst targets implying nearly 100% upside but binary downside risk. The consensus is Strong Buy (1.17/5) with an average target of $163.45, suggesting significant upside if the catalyst succeeds.
Supporting Evidence: The stock has no revenue but is valued at $5.2B market cap, reflecting the potential of gedatolisib. The forward P/E of 86x implies aggressive profitability expectations, but the average analyst target of $163.45 offers 97.8% upside. The company has a strong current ratio of 10.55, providing a cash runway into 2027. The Phase 3 trial completion de-risks the primary catalyst. However, the P/B of 52.1x is extreme, and the negative EBITDA of -$46.7M in Q1 2026 highlights the lack of current earnings.
Risks & Conditions: The biggest risk is FDA non-approval, which could send shares below $20. A delay or narrow label could also pressure the stock. This Speculative Buy would upgrade to a Buy if the FDA approves gedatolisib with a broad label, or downgrade to Hold if the PDUFA date passes without approval. The stock is overvalued on traditional metrics (P/B 52x, no revenue) but fairly valued relative to the binary catalyst potential. Investors should size positions accordingly.
Sign up to view all
CELC 12-Month Price Forecast
The AI assessment is bullish with medium confidence, driven by the strong analyst consensus and completed Phase 3 trial. However, the binary nature of the FDA catalyst and extreme valuation multiples warrant caution. The stock's 45% decline from its 52-week high provides a better risk/reward entry compared to earlier levels. The key factor to watch is the FDA decision; a positive outcome could drive the stock to $150+, while a negative outcome could lead to an -80% loss. The stance would upgrade to high confidence if the FDA accepts the NDA with priority review, and downgrade to neutral if the PDUFA date is extended.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celcuity Inc. Common Stock's 12-month outlook, with a consensus price target around $163.54 and implied upside of +98.8% versus the current price.
Average Target
$163.54
0 analysts
Implied Upside
+98.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$148 - $178
Analyst target range
Celcuity is covered by 11 analysts, with a consensus recommendation of 'Strong Buy' (mean 1.17 on a 1-5 scale). The distribution is heavily bullish: 10 buys, 1 hold, 0 sells. The average target price is $163.45, implying a 97.8% upside from the current price of $82.62. The consensus is strongly bullish, driven by the potential FDA approval of gedatolisib. The target range spans from a low of $147.00 to a high of $178.00, representing a 21.1% spread between low and high. The high target of $178.00 assumes successful FDA approval, strong commercial uptake, and potential multiple expansion. The low target of $147.00 still implies a 77.9% upside, suggesting analysts see limited downside risk even in a conservative scenario. Recent ratings actions show no downgrades; all actions have been reaffirmations or upgrades (e.g., HC Wainwright upgraded from Neutral to Buy in May 2026). The tight target range (21% spread) indicates relatively high conviction among analysts, though the wide gap between current price and targets highlights the binary nature of the FDA catalyst.
Bulls vs Bears: CELC Investment Factors
Celcuity presents a high-risk, high-reward binary opportunity. The bull case is supported by a unanimous Strong Buy analyst consensus, 97.8% average upside to targets, and a completed Phase 3 trial for gedatolisib. However, the bear case highlights zero revenue, widening losses, extreme valuation multiples (P/B 52x, forward P/E 86x), and binary FDA risk. The single most important tension is the FDA approval decision: if positive, the stock could rally to $150+; if negative, it could fall below $20. Currently, the evidence slightly favors the bulls given analyst conviction and trial progress, but the risk of a -75%+ drawdown in a bear case makes this a speculative position.
Bullish
- Strong Buy Analyst Consensus: 11 analysts rate CELC a Strong Buy (mean 1.17/5), with an average target of $163.45, implying 97.8% upside from $82.62. The tight target range ($147-$178) reflects high conviction in gedatolisib's approval.
- Massive Upside to Analyst Targets: Even the low analyst target of $147 implies 77.9% upside. The high target of $178 suggests 115.4% potential gain, driven by successful FDA approval and commercial launch.
- Phase 3 VIKTORIA-1 Enrollment Complete: The pivotal trial for gedatolisib in HR+/HER2- breast cancer has completed enrollment and reported results for PIK3CA WT tumors, de-risking the primary catalyst. Cohort 2 (PIK3CA MT) is also enrolled.
- Strong Institutional Conviction: Recent news highlights a $170 million fund bet and a $17 million insider buy, signaling high confidence in the FDA review. Institutional accumulation supports the bullish thesis.
Bearish
- Zero Revenue and Deep Losses: Celcuity has no revenue and reported a net loss of -$52.8M in Q1 2026, widening from -$37.0M a year ago. TTM free cash flow is -$172.9M, indicating heavy cash burn with no near-term product sales.
- Extreme Valuation Multiples: P/B ratio of 52.1x is extremely high, and forward P/E of 86x implies aggressive profitability expectations. EV/EBITDA is -33x, reflecting negative EBITDA. Any delay in approval could trigger severe multiple compression.
- Binary FDA Risk: The stock's valuation hinges entirely on FDA approval of gedatolisib. A negative FDA decision or complete response letter could send shares below $20, as the company has no other near-term catalysts.
- Recent Price Momentum Negative: The stock has declined 45.3% from its 52-week high of $151.02, with a 1-month drop of -14.3% and 3-month drop of -31.7%. This technical weakness suggests profit-taking and uncertainty ahead of the FDA decision.
CELC Technical Analysis
Celcuity is in a sharp downtrend from its 52-week high of $151.02, with the current price of $82.62 representing a 45.3% decline from that peak. The stock has gained 488% over the past year, but the 1-year price change masks the recent weakness; the current price sits at 54.7% of the 52-week range (midpoint), indicating a significant pullback from overbought levels. This positioning suggests the stock is in a correction phase after an extraordinary rally, with potential support near the 52-week low of $13.59, though that level is far below current prices. The 1-month price change of -14.3% and 3-month change of -31.7% confirm accelerating downside momentum, diverging sharply from the 1-year uptrend. This divergence signals a potential trend reversal or a severe pullback, as short-term selling pressure overwhelms the longer-term bullish narrative. The RSI is not provided, but the steep decline in volume (recent volume of 1.29 million) may indicate panic selling or profit-taking. The 52-week high of $151.02 acts as strong resistance, while the 52-week low of $13.59 is distant support; a break below $82.62 could open the door to further losses toward the $70 area. Beta is 0.164, meaning the stock is far less volatile than the market, which is unusual given its price swings—this low beta may be a statistical artifact or reflect limited correlation with broad market moves. A breakout above $151.02 would signal a resumption of the uptrend, but a breakdown below recent lows would confirm a bearish phase.
Beta
0.16
0.16x market volatility
Max Drawdown
-43.3%
Largest decline past year
52-Week Range
$34-$151
Price range past year
Annual Return
+497.5%
Cumulative gain past year
| Period | CELC Return | S&P 500 |
|---|---|---|
| 1m | -17.7% | +1.4% |
| 3m | -31.5% | +3.9% |
| 6m | -28.2% | +6.3% |
| 1y | +497.5% | +16.0% |
| ytd | -18.2% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CELC Fundamental Analysis
Celcuity has zero revenue, as it is a pre-commercialization biotech. The most recent quarterly revenue (Q1 2026) was $0, with a YoY growth rate of 0%, and the multi-quarter trend shows no revenue generation. The company's growth trajectory is entirely dependent on the success of its clinical trials and eventual FDA approval; there are no revenue segments to analyze. The investment case hinges on the potential approval of gedatolisib, not current revenue. The company is deeply unprofitable, with a net loss of -$52.8 million in Q1 2026, compared to -$37.0 million in Q1 2025, indicating widening losses. Gross margin is 0% (negative gross profit of -$47,000 in Q1 2026), typical for a clinical-stage biotech with no product sales. Operating expenses (R&D of $33.1 million and SG&A of $17.4 million) are rising as trials progress, and net income is negative. The trajectory is away from profitability, as losses are increasing, which is expected for a company investing heavily in late-stage trials. Celcuity has a debt-to-equity ratio of 1.94, indicating significant leverage, and a current ratio of 10.55, suggesting ample short-term liquidity. Free cash flow was -$55.3 million in Q1 2026, and TTM FCF is -$172.9 million, meaning the company is burning cash to fund operations. ROE is -176%, reflecting severe losses relative to equity. The company relies on external financing (equity and debt) to fund its cash burn, as evidenced by recent capital raises. The high debt-to-equity and negative FCF signal financial risk, but the strong current ratio provides a cushion for the near term.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-172930000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CELC Overvalued?
Since net income is negative, the P/E ratio is not meaningful; we use the price-to-sales (P/S) ratio. However, Celcuity has zero revenue, so the P/S ratio is undefined (0). Instead, we use enterprise value to EBITDA (EV/EBITDA), which is -32.99, indicating the company has negative EBITDA. The trailing P/E is -26.39, and the forward P/E is 86.06, implying the market expects profitability in the future. The gap between negative trailing and positive forward P/E reflects high growth expectations for earnings. The stock's P/B ratio is 52.11, compared to the industry average (not provided, but typically lower for biotech). Without sector averages, we note that a P/B of 52x is extremely high, suggesting the market values the company's assets at a significant premium, likely due to its pipeline potential. The EV/EBITDA of -32.99x is negative, indicating the company is not generating positive EBITDA. Historically, the P/B ratio has ranged from 1.77 (Dec 2022) to 116.14 (Mar 2026), and the current 52.11x is near the middle of that range. The P/E trailing has ranged from -29.42 to -2.75, and the current -26.39 is near the most negative (worst) historical levels, reflecting deeper losses. This suggests the market is pricing in optimistic future earnings, as the forward P/E of 86x implies a sharp turnaround.
PE
-26.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-33.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Celcuity has zero revenue and is deeply unprofitable, with a net loss of -$52.8M in Q1 2026, up from -$37.0M a year ago. The company burns cash at a TTM free cash flow of -$172.9M, and its debt-to-equity ratio of 1.94 indicates significant leverage. While the current ratio of 10.55 provides near-term liquidity, the company will likely need additional financing, which could dilute shareholders. The negative ROE of -176% and negative EBITDA highlight severe operational inefficiency typical of a pre-commercial biotech.
Market & Competitive Risks: The stock trades at extreme valuation multiples, with a P/B of 52.1x and forward P/E of 86x, implying the market is pricing in successful FDA approval and rapid revenue growth. Any setback in the approval process could trigger a sharp de-rating. The low beta of 0.164 suggests limited correlation with the market, but the stock is highly sensitive to company-specific news. Competition from other PI3K/AKT/mTOR inhibitors (e.g., Novartis's alpelisib) could limit gedatolisib's commercial potential. Recent news of insider buying provides some support, but the stock's 45% decline from its 52-week high indicates growing skepticism.
Worst-Case Scenario: The most damaging scenario is an FDA rejection or complete response letter for gedatolisib, which would eliminate the primary value driver. In this case, the stock could fall to its 52-week low of $13.59, representing a -83.5% decline from the current price of $82.62. Even a delay in approval or a narrow label could push the stock below $50. The historical max drawdown of -43.01% has already been exceeded in the current pullback, but a worst-case scenario could see losses exceeding -80%.
FAQ
The primary risk is FDA non-approval of gedatolisib, which could cause the stock to fall to the 52-week low of $13.59, an -83.5% loss. Financial risks include zero revenue, widening losses (-$52.8M in Q1 2026), and negative free cash flow of -$172.9M TTM, requiring future dilution. Valuation risk is extreme, with a P/B of 52.1x and forward P/E of 86x, leaving no room for error. Competitive risk comes from existing PI3K inhibitors like alpelisib. The stock's low beta of 0.164 offers no diversification benefit.
The 12-month forecast is binary. In the bull case (30% probability), FDA approval drives the stock to $147-$178, with a high target of $178. In the base case (45% probability), approval with restrictions leads to $100-$147. In the bear case (25% probability), rejection sends the stock to $13.59-$50. The most likely scenario is the base case, assuming FDA approval with a moderate label. The average analyst target of $163.45 implies a 97.8% upside, but the wide range reflects high uncertainty.
Celcuity is overvalued on traditional metrics but may be fairly valued relative to its binary catalyst. The P/B ratio of 52.1x is extremely high, and the forward P/E of 86x implies aggressive profitability expectations. The EV/EBITDA of -33x reflects negative EBITDA. However, the stock's valuation is driven by the potential of gedatolisib, not current earnings. Compared to the analyst average target of $163.45, the current price of $82.62 suggests a 97.8% discount to that target, implying the market is pricing in significant risk of failure. The stock is overvalued on a fundamental basis but could be undervalued if the drug is approved.
Celcuity is a high-risk, high-reward speculative buy. The stock has a Strong Buy analyst consensus with an average target of $163.45, implying 97.8% upside from $82.62. However, the company has zero revenue, negative earnings, and a market cap of $5.2B that depends entirely on FDA approval of gedatolisib. The biggest downside risk is a -83.5% decline to the 52-week low of $13.59 if the FDA rejects the drug. For investors with a high risk tolerance and a long-term horizon, it could be a good buy if they believe in the drug's approval. Conservative investors should avoid it.
Celcuity is best suited for short-to-medium-term trading around the FDA catalyst, as the stock's value is binary and will be resolved within 12 months. The low beta of 0.164 means it is not correlated with the market, making it unsuitable for long-term buy-and-hold strategies. The company has no revenue or earnings, so long-term investors would rely entirely on successful commercialization, which is uncertain. A minimum holding period of 6-12 months is recommended to capture the FDA decision. Short-term traders should be aware of high volatility, as seen in the 45% decline from the 52-week high.